Ad26.ZIKV.001

Drug Profile

Ad26.ZIKV.001

Alternative Names: JNJ-66684657

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Vaccines and Prevention B.V
  • Class Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 26 Nov 2017 Phase-I clinical trials in Zika virus infection (In volunteers) in USA (IM) (NCT03356561)
  • 25 Nov 2017 Preclinical trials in Zika virus infection (In volunteers) in Netherlands (IM) before November 2017
  • 25 Nov 2017 Janssen plans a phase I trial for Zika virus infection USA (NCT03356561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top